98%
921
2 minutes
20
T-cell Prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell malignancy that follows an aggressive clinical course. The classical presentation includes an elevated white blood cell (WBC) count with anemia and thrombocytopenia, hepatosplenomegaly, and lymphadenopathy. T-PLL is a disease of the elderly and to our knowledge it has never been described in the pediatric age group. We report a case of T-PLL in a 9 year old male who was initially diagnosed with T-cell acute lymphoblastic lymphoma (ALL), the diagnosis was later refined to T-PLL following additional analysis of bone marrow morphology and immunophenotype. Two unusual findings in our patient included CD117 expression and an isolated chromosomal 12(p13) deletion. The patient failed to respond to standard ALL induction chemotherapy, but achieved complete remission following treatment with a fludarabine and alemtuzumab-based regimen.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514102 | PMC |
http://dx.doi.org/10.1186/2162-3619-1-7 | DOI Listing |
Case Rep Hematol
August 2025
Clinical Haematology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia.
T-cell prolymphocytic leukaemia (T-PLL) is an aggressive and rare post-thymic T cell malignancy, highly refractory to conventional cytotoxic chemotherapeutics. While extranodal involvement is common, solid organ invasion is rare. We present the case of a 76-year-old man who developed acute renal failure secondary to T-PLL renal infiltration.
View Article and Find Full Text PDFJ Emerg Med
July 2025
Department of Emergency Medicine, Kinmen Hospital, Ministry of Health and Welfare, Kaohsiung, Taiwan.
Background: Pseudohyperkalemia is characterized by a falsely elevated serum potassium concentration, often due to cellular disruption during blood sample collection, processing, or transport. Accurate differentiation between pseudohyperkalemia and true hyperkalemia is vital to prevent inappropriate treatment, which can lead to iatrogenic hypokalemia.
Case Report: We present a case of a 67-year-old woman with hypertension and T-cell prolymphocytic leukemia who presented to the emergency department with fever and hypotension.
Blood Adv
August 2025
University Medical Center Goettingen, Goettingen, Germany.
Mature T-cell leukemias and lymphomas (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies.
View Article and Find Full Text PDFAm J Clin Pathol
July 2025
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
This session included 51 cases submitted to the workshop "Progress in T- and NK-cell Lymphomas and Leukemias" by the Society for Hematopathology and European Association for Haematopathology under "Blood/Bone Marrow-Based Mature T- and NK-Cell Leukemias/Lymphomas" or "T/NK-cell neoplasms with a Leukemic Presentation." Entities encompassed T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia (LGLL), natural killer (NK)-LGLL/chronic lymphoproliferative disorder of NK cells, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia, and their mimics. Submitted cases illustrated classic and variant morphology, immunophenotype, and clinical features; the overlaps with reactive T-cell /NK-cell lymphoproliferations; and challenges in differentiating these entities from other T-cell/NK-cell neoplasms with a leukemic presentation.
View Article and Find Full Text PDFPediatr Blood Cancer
September 2025
Department of Pediatrics, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patients with ataxia-telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B-cell lymphoma, alemtuzumab for T-cell prolymphocytic leukemia, and venetoclax for early T-cell precursor acute lymphoblastic leukemia. These cases highlight the potential of targeted agents to improve outcomes while minimizing toxicity.
View Article and Find Full Text PDF